LifeMD, Inc. beat EPS estimates 50% of the time across 14 reported quarters (7 beats, 7 misses), averaging -11.3% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.20 | $-0.16 | +20.0% | Beat | |
| Q1 FY26 | $-0.14 | $-0.20 | -42.9% | Miss | |
| Q4 FY25 | not reported | $-0.04 | not reported | not reported | |
| Q3 FY25 | $-0.06 | $-0.10 | -66.7% | Miss | |
| Q2 FY25 | not reported | $-0.06 | not reported | not reported | |
| Q1 FY25 | not reported | $0.01 | not reported | not reported | |
| Q4 FY24 | not reported | $-0.02 | not reported | not reported | |
| Q3 FY24 | $-0.10 | $-0.14 | -40.0% | Miss | |
| Q2 FY24 | $-0.13 | $-0.19 | -46.1% | Miss | |
| Q1 FY24 | $-0.13 | $-0.19 | -46.1% | Miss | |
| Q4 FY23 | $-0.14 | $-0.12 | +14.3% | Beat | |
| Q3 FY23 | $-0.18 | $-0.20 | -11.1% | Miss |
Back to LFMD overview · LFMD holders · LFMD KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.